Atorvastatin Effectiveness and Safety in Cardiology Patients in Real World Setting (ATTENTION)

Viatris

Status: Completed

Conditions: Coronary Artery Disease, Hypercholesterolemia, Hypertension

Treatments: Other: No intervention

Study type: Observational

Funder types: Industry

Identifiers

NCT02565615

A2581197

Details and patient eligibility

About

The study is to verify atorvastatin effectiveness and safety in Chinese population, and explore the optimal atorvastatin regimens in high-to-moderate risk for ASCVD。

Enrollment: 5,115 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Men and women aged ≥18 years;
• Cardiology patients who has been prescribed atorvastatin by physician's clinical judgment under normal clinical care. These patients will include those with established coronary heart disease, or having multiple risk factors and at risk for cardiovascular disease, or primary hypercholesterolemia.
• Baseline laboratory reports prior to starting atorvastatin therapy can be tracked , including lipid measurement, liver function, and Creatine Kinase (CK) value. The date of baseline reports should be within 1 month before taking atorvastatin or within 24h after starting atorvastatin therapy.
• Evidence of a personally or his/her legally acceptable representative signed and dated informed consent document indicating that the patient has been informed of all pertinent aspects of the study and accept follow-up visit.

Exclusion criteria

• Patients who have regularly taken atorvastatin therapy more than 4 weeks before enrollment
• Concomitant any other lipid-lower medication at baseline, or during the study conduction on physician clinical judgement

Trial design

5,115 participants in 1 patient group

Atorvastatin dose titration (single-arm)

Description:

Judged by investigators, patients in cardiology department who are using atorvastatin can be included into this study, if they are eligible. During the study, the dose can be titrated based on the judgement of investigator

Treatment:

Other: No intervention